🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 06 Jul 2026 · EMA CTIS official data

Clinical Trials in France

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

219
Recent authorisations
107
Phase III trials
France
Selected country
Phase I/II Neoplasms Authorised 03/07/2026
A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors
Solid tumors
Larkspur Biosciences Inc. · 80 participants
📍 France
2026-525629-20-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 02/07/2026
Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment
myeloproliferative neoplasms
Centre Hospitalier Regional Et Universitaire De Brest · 50 participants
📍 France
2025-523921-17-00 on CTIS ↗
Phase II Diagnosis Authorised 02/07/2026
18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)
Patients (male or female) ≥18 years old with Suspected functional pituitary adenoma (prolactinoma, Cushing's disease, acromegaly, thyrotropic adenoma), de novo or recurrence/persistence, With indeterminate pituitary MRI.
Centre Hospitalier Universitaire De Lille · 30 participants
📍 France
2025-523829-17-00 on CTIS ↗
Phase II Neoplasms Authorised 02/07/2026
IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer
Stage III Non Small Cell Lung Cancer
Intergroupe Francophone De Cancerologie Thoracique · 177 participants
📍 France
2025-522801-39-00 on CTIS ↗
Phase I/II Neoplasms Authorised 01/07/2026
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ideaya Biosciences Inc. · 35 participants
📍 France · Spain
2025-523438-24-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"
Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 181 participants
📍 Spain · Czechia · France · Italy · Germany · Greece
2025-523815-12-00 on CTIS ↗
Phase III Neoplasms Authorised 01/07/2026
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S · 189 participants
📍 Finland · Belgium · France · Denmark · Austria · Germany · Italy · Czechia · Norway
2025-522167-15-00 on CTIS ↗
Phase I/II Neoplasms Authorised 30/06/2026
A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs
solid tumor
Krystal Biotech Inc. · 40 participants
📍 France · Spain
2025-522723-98-00 on CTIS ↗
Phase III Immune System Diseases Authorised 30/06/2026
Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)
Eosinophilic Disease
AstraZeneca AB · 5 participants
📍 Netherlands · France
2023-508533-14-00 on CTIS ↗
Phase III Neoplasms Authorised 30/06/2026
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Non Small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc. · 45 participants
📍 Spain · Belgium · France · Italy · Germany
2025-521971-29-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc. · 128 participants
📍 Greece · France · Italy · Belgium · Denmark · Germany · Czechia · Portugal · Austria
2025-521769-29-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/06/2026
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome
Dravet Syndrome
Ionis Pharmaceuticals Inc. · 10 participants
📍 France · Belgium · Portugal · Germany
2025-523835-20-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 30/06/2026
A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
Participants with relapsed HRNB and participants with HRNB refractory to treatment The clinical trial will recruit participants aged ≥18 months to <18 years, and therefore all participants will be minors at the time of consent.
Renaissance Pharma Limited · 56 participants
📍 France · Denmark · Ireland · Germany
2025-524397-42-00 on CTIS ↗
Phase III Immune System Diseases Authorised 29/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA · 46 participants
📍 Spain · Belgium · France · Germany · Slovakia · Bulgaria · Italy · Greece
2025-523871-44-00 on CTIS ↗
Phase III Not possible to specify Authorised 29/06/2026
Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial
Non-traumatic pain
Centre Hospitalier Regional Universitaire De Tours · 164 participants
📍 France
2025-525001-21-00 on CTIS ↗
Phase II Neoplasms Authorised 29/06/2026
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer
Small Cell Lung Cancer
Pfizer Inc. · 9 participants
📍 France · Italy
2025-524686-24-00 on CTIS ↗
Phase II Mental Disorders Authorised 29/06/2026
Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA
Alcoholism
Institut National De La Sante Et De La Recherche Medicale · 60 participants
📍 France
2025-524148-36-00 on CTIS ↗
Phase I/II Neoplasms Authorised 29/06/2026
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
Solid Tumors
Revolution Medicines Inc. · 227 participants
📍 France · Spain · Greece · Germany · Italy · Sweden · Belgium
2025-524623-50-00 on CTIS ↗
Phase III Neoplasms Authorised 26/06/2026
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Pancreatic Ductal Adenocarcinoma
Incyte Corp. · 205 participants
📍 Poland · Italy · Netherlands · Sweden · Denmark · Finland · Spain · France · Belgium · Norway · Austria
2025-525009-18-00 on CTIS ↗
Phase I Neoplasms Authorised 26/06/2026
A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb Services Unlimited Company · 22 participants
📍 France
2024-513987-24-00 on CTIS ↗
Phase II Eye Diseases Authorised 25/06/2026
An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration
Geographic atrophy secondary to age-related macular degeneration
PulseSight Therapeutics · 24 participants
📍 France
2025-525008-12-00 on CTIS ↗
Phase IV Diagnosis Authorised 25/06/2026
ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment
prostate cancer
Centre Hospitalier Universitaire De Toulouse · 30 participants
📍 France
2026-525181-22-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 24/06/2026
A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
Multiple Sclerosis
F. Hoffmann-La Roche AG · 54 participants
📍 Spain · France · Poland · Italy
2025-523726-40-00 on CTIS ↗
Phase III Mental Disorders Authorised 24/06/2026
Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)
Post-traumatic stress disorder (PTSD)
Centre Hospitalier Universitaire De Toulouse · 76 participants
📍 France
2025-523107-30-01 on CTIS ↗
Phase I Immune System Diseases Authorised 24/06/2026
THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom
IPEX syndrome is a primary immunodeficiency caused by hemizygous mutations in the gene FOXP3, which encodes an essential transcription factor required to maintain immunological tolerance by thymus-derived regulatory T (Treg) cells., Patients affected by IPEX syndrome, proven by molecular diagnosis, with any active autoimmune complications or controlled under immunosuppressive therapy can be enrolled in this trial.
Assistance Publique Hopitaux De Paris · 5 participants
📍 France
2025-523305-15-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 23/06/2026
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).
Non-cystic fibrosis bronchiectasis
Sanofi-Aventis Recherche & Developpement · 41 participants
📍 Poland · Spain · France · Netherlands · Germany
2025-523403-29-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 23/06/2026
Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone
Small for gestational age (SGA) and idiopathic short stature (ISS)
Schneider Children's Medical Center Of Israel · 95 participants
📍 Greece · Poland · France · Czechia
2025-523832-38-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 23/06/2026
ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
patients with influenza-induced acute hypoxemic respiratory failure
Centre Hospital Region Metz Thionville · 544 participants
📍 France
2025-524976-40-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 23/06/2026
An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis (RRMS)
F. Hoffmann-La Roche AG · 9 participants
📍 Poland · Germany · France
2025-524164-37-00 on CTIS ↗
Phase III Immune System Diseases Authorised 22/06/2026
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Hereditary Angioedema
Adarx Pharmaceuticals Inc. · 45 participants
📍 Poland · Italy · Hungary · France · Austria · Czechia · Belgium · Spain · Bulgaria · Germany · Croatia
2025-521353-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/06/2026
Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy
HCC – Hepatocellular Carcinoma
Centr Georges Francois Leclerc · 30 participants
📍 France
2026-526324-48-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC · 467 participants
📍 Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).
Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc. · 88 participants
📍 Germany · France · Poland · Italy · Spain
2025-524488-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 22/06/2026
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis
Colitis ulcerative
Merck Sharp & Dohme LLC · 44 participants
📍 Italy · Greece · Netherlands · Poland · Germany · France
2025-523479-49-00 on CTIS ↗
Phase II Neoplasms Authorised 22/06/2026
Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Verastem Inc. · 4 participants
📍 France
2025-524713-88-00 on CTIS ↗
Phase IV Musculoskeletal Diseases Authorised 22/06/2026
Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
Metachromatic leukodystrophy
Orchard Therapeutics (Europe) Limited · 29 participants
📍 Netherlands · Germany · Italy · Sweden · France
2025-522275-28-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 22/06/2026
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)
Osteogenesis Imperfecta
Angitia Inc. Ltd. · 40 participants
📍 Netherlands · France · Denmark
2025-522951-24-00 on CTIS ↗
Phase III Immune System Diseases Authorised 19/06/2026
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)
Systemic Sclerosis
Celgene Corp. · 33 participants
📍 Spain · Germany · France · Italy
2025-524337-11-00 on CTIS ↗
Phase I/II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 18/06/2026
Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product
Ornithine Transcarbamylase Deficiency (OTC)
Iecure Inc. · 3 participants
📍 Spain · France
2024-514190-21-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 18/06/2026
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR · 110 participants
📍 Spain · Germany · Italy · Sweden · France · Luxembourg
2024-513496-40-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 17/06/2026
Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial
Osteoporotic Fracture
University Hospital Of Clermont-Ferrand · 30 participants
📍 France
2025-524889-25-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 17/06/2026
STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
ulcerative colitis
Centre Hospitalier Regional De Marseille · 224 participants
📍 France
2026-525643-32-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company · 318 participants
📍 Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 17/06/2026
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period
Systemic sclerosis
Galderma S.A. · 56 participants
📍 Poland · Italy · Bulgaria · France · Greece · Spain · Croatia
2025-522294-11-00 on CTIS ↗
Phase I Neoplasms Authorised 16/06/2026
Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer
Solid Tumors
Theras Inc. · 2999997 participants
📍 Spain · Italy · France
2025-524690-16-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Expressing Claudin18.2
AstraZeneca AB · 516 participants
📍 France · Italy · Spain · Hungary · Poland · Belgium · Germany · Netherlands
2024-519787-40-00 on CTIS ↗
Phase III Neoplasms Authorised 16/06/2026
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Stage I NSCLC
Merck Sharp & Dohme LLC · 283 participants
📍 Greece · Poland · Italy · Hungary · Germany · Netherlands · France · Spain
2025-522643-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc. · 228 participants
📍 Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 15/06/2026
Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms
Heart failure
Centre Hospitalier Universitaire De Montpellier · 1050 participants
📍 France
2025-524344-35-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 15/06/2026
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica
Musculoskeletal diseases
Sanofi-Aventis Recherche & Developpement · 177 participants
📍 France · Netherlands · Germany · Czechia · Belgium · Austria · Hungary · Greece · Spain
2024-511296-15-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 15/06/2026
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)
Swedish Orphan Biovitrum AB (publ) · 69 participants
📍 France · Italy · Spain · Germany
2025-524487-37-00 on CTIS ↗
Phase II Diagnosis Authorised 13/06/2026
Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis
Transthyretin cardiac amyloidosis
Centre Hospitalier Universitaire De Nantes · 40 participants
📍 France
2025-523616-36-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation​
Merck Sharp & Dohme LLC · 88 participants
📍 Italy · Netherlands · France · Germany · Spain · Poland · Greece
2025-522038-29-00 on CTIS ↗
Phase I Not possible to specify Authorised 12/06/2026
A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.
Not applicable for phase I study
Antabio · 40 participants
📍 France
2026-526411-11-00 on CTIS ↗
Phase III Neoplasms Authorised 12/06/2026
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
Merck Sharp & Dohme LLC · 109 participants
📍 Greece · Netherlands · Sweden · France · Italy · Spain · Denmark
2025-522267-15-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 12/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 210 participants
📍 Greece · Germany · Belgium · Netherlands · Poland · Italy · France · Spain · Bulgaria · Austria
2025-523674-16-00 on CTIS ↗
Phase II Neoplasms Authorised 11/06/2026
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ, and esophageal adenocarcinomas
Gilead Sciences Inc. · 45 participants
📍 Spain · France
2025-524095-27-00 on CTIS ↗
Phase I/II Not possible to specify Authorised 10/06/2026
ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Assistance Publique Hopitaux De Paris · 36 participants
📍 France
2025-524728-22-01 on CTIS ↗
Phase III Neoplasms Authorised 10/06/2026
First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)
Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resected
Institut Gustave Roussy · 504 participants
📍 France
2025-523593-16-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 10/06/2026
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC)
Eli Lilly & Co. · 104 participants
📍 Latvia · Portugal · Greece · France · Czechia · Italy · Poland · Slovakia · Hungary · Croatia · Lithuania
2025-524404-29-00 on CTIS ↗
Phase III Neoplasms Authorised 09/06/2026
Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
Advanced lymphoid leukemia
Institut De Recherches Internationales Servier IRIS · 1 participants
📍 France
2026-526212-37-00 on CTIS ↗
Phase III Neoplasms Authorised 09/06/2026
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.
Follicular Lymphoma
Merck Sharp & Dohme LLC · 5 participants
📍 France · Spain
2025-522777-10-00 on CTIS ↗
Phase I/II Neoplasms Authorised 09/06/2026
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Advanced KRAS G12D-Mutant Solid Tumors
Verastem Inc. · 210 participants
📍 Italy · France · Germany · Belgium · Spain · Netherlands
2025-523432-39-01 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)
Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc. · 496 participants
📍 Norway · Czechia · Portugal · Austria · Poland · France · Spain
2025-522176-86-01 on CTIS ↗
Phase I Mental Disorders Authorised 08/06/2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers
Schizophrenia
Syremis Therapeutics Ltd. · 280 participants
📍 France
2026-525700-10-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 08/06/2026
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
Nonsegmental vitiligo
Novartis Pharma AG · 80 participants
📍 Germany · Spain · Netherlands · France · Italy
2025-522301-37-00 on CTIS ↗
Phase II Neoplasms Authorised 08/06/2026
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).
Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Gilead Sciences Inc. · 94 participants
📍 Spain · Italy · France
2025-523984-39-00 on CTIS ↗
Phase III Neoplasms Authorised 08/06/2026
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC)
Zai Lab (US) LLC · 234 participants
📍 Belgium · Czechia · Germany · Denmark · Greece · Netherlands · Poland · Spain · Austria · Italy · France
2025-522818-23-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 08/06/2026
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Pfizer Inc. · 318 participants
📍 Spain · Germany · Poland · Czechia · Greece · Italy · Bulgaria · France · Hungary
2024-518587-12-00 on CTIS ↗
Phase IV Immune System Diseases Authorised 08/06/2026
PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
granulomatosis with polyangiitis and microscopic polyangiitis
Assistance Publique Hopitaux De Paris · 70 participants
📍 France
2025-522049-23-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/06/2026
KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer; advanced solid tumors harboring the KRAS G12C mutation.
Novartis Pharma AG · 31 participants
📍 Spain · Italy · France · Denmark · Belgium
2025-523537-26-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 08/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited · 173 participants
📍 Belgium · Greece · Poland · France · Spain · Bulgaria · Italy · Germany · Austria · Netherlands
2025-523675-39-00 on CTIS ↗
Phase III Anesthesia and Analgesia Authorised 05/06/2026
OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery
indication for pulmonary resection surgery (segmentectomy or lobectomy), video-assisted thoracoscopy or scheduled robot-assisted surgery.
Centre Hospitalier Universitaire De Rennes · 176 participants
📍 France
2025-524240-35-00 on CTIS ↗
Phase III Mental Disorders Authorised 05/06/2026
ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms
Alcohol use disorder, depressive symptoms
Centre Hospitalier Universitaire De Nimes · 172 participants
📍 France
2025-525069-65-00 on CTIS ↗
Phase III Neoplasms Authorised 05/06/2026
PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence
Participants with R0/R1 resected liver metastases from colorectal cancer (CRLM).
Unicancer · 272 participants
📍 France
2025-523913-27-00 on CTIS ↗
Phase IV Bacterial Infections and Mycoses Authorised 05/06/2026
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis
Infection prophylaxis
Assistance Publique Hopitaux De Paris · 10 participants
📍 France
2025-521988-13-00 on CTIS ↗
Phase II Investigative Techniques Authorised 05/06/2026
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy
Septic Coagulopathy
Les Hopitaux Universitaires De Strasbourg · 120 participants
📍 France
2025-523397-16-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/06/2026
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 250 participants
📍 Austria · Slovakia · Portugal · Czechia · Hungary · Spain · France · Denmark · Italy · Croatia
2025-524894-17-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 04/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Narcolepsy Type 2
Alkermes Inc. · 98 participants
📍 Spain · Netherlands · Belgium · Italy · France
2025-523912-35-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 04/06/2026
TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH
Aneurysmal subarachnoid hemorrhage
Centre Hospitalier Universitaire De Toulouse · 274 participants
📍 France
2023-509795-42-00 on CTIS ↗
Phase I/II Neoplasms Authorised 04/06/2026
REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.
Patients with poor prognostic ovarian cancers based on the tumor primary chemonsensitivity and incomplete debulking surgery.
Asso De Recherche Cancers Gynecologiques · 43 participants
📍 France
2025-524232-20-00 on CTIS ↗
Phase I/II Neoplasms Authorised 02/06/2026
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.
Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma Inc. · 180 participants
📍 Spain · Ireland · Italy · France · Romania
2025-523590-42-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 02/06/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Narcolepsy Type 1
Alkermes Inc. · 75 participants
📍 Italy · France · Netherlands · Spain · Belgium
2025-523911-13-00 on CTIS ↗
Phase III Immune System Diseases Authorised 02/06/2026
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
Systemic lupus erythematosus
AstraZeneca AB · 97 participants
📍 Poland · Germany · Italy · France · Spain
2025-523670-17-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG · 42 participants
📍 France · Austria · Poland · Netherlands · Spain · Denmark · Italy · Germany · Hungary
2025-522434-32-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 01/06/2026
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
Asthma
Novartis Pharma AG · 68 participants
📍 Poland · France · Slovakia · Spain · Hungary · Germany · Romania
2022-502365-26-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 01/06/2026
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
Hemophilia A
F. Hoffmann-La Roche AG · 124 participants
📍 Hungary · Spain · Ireland · Poland · Austria · Germany · Denmark · Belgium · Netherlands · Italy · France
2025-522435-33-00 on CTIS ↗
Phase III Neoplasms Authorised 01/06/2026
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
Treatment-naїve mantle cell lymphoma (MCL)
Innocare Pharma Inc. · 102 participants
📍 Poland · France · Czechia · Spain · Romania
2025-524241-27-00 on CTIS ↗
Phase III Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
MOOD - MethOxyflurane analgesia in vasoOcclusive crises of sickle cell Disease
Sickle cell disease
Assistance Publique Hopitaux De Paris · 198 participants
📍 France
2024-518043-38-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 29/05/2026
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
Centre Hospitalier De Versailles · 86 participants
📍 Germany · France · Czechia · Netherlands · Spain
2024-516570-30-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 29/05/2026
Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS
Restless legs syndrome
Centre Hospitalier Universitaire De Montpellier · 60 participants
📍 France
2026-525613-31-00 on CTIS ↗
Phase IV Cardiovascular Diseases Authorised 29/05/2026
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study
heart failure
Centre Hospitalier Universitaire De Toulouse · 458 participants
📍 France
2025-524395-30-00 on CTIS ↗
Phase III Neoplasms Authorised 29/05/2026
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
Myelofibrosis
Novartis Pharma AG · 173 participants
📍 Belgium · Germany · Austria · Poland · Spain · Italy · Netherlands · Czechia · France
2025-523555-66-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 29/05/2026
Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.
Retractile Capsulitis
Centre Hospitalier Universitaire De Nantes · 38 participants
📍 France
2026-525317-31-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
Cystic fibrosis
Vertex Pharmaceuticals Inc. · 80 participants
📍 Spain · Sweden · Germany · Italy · Belgium · Czechia · Ireland · Portugal · Netherlands · France · Denmark
2025-523400-72-00 on CTIS ↗
Phase II Neoplasms Authorised 28/05/2026
Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)
Locally advanced high‑risk stage III rectal adenocarcinoma (non‑metastatic)
Institut Gustave Roussy · 24 participants
📍 France
2025-524378-40-00 on CTIS ↗
Phase II Neoplasms Authorised 28/05/2026
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences Inc. · 34 participants
📍 Bulgaria · France · Spain
2025-523539-20-00 on CTIS ↗
Phase I/II Neoplasms Authorised 28/05/2026
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Merck Sharp & Dohme LLC · 73 participants
📍 Poland · Italy · France · Germany · Spain
2025-523005-15-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 27/05/2026
Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.
The medical condition studied in IMMUNO-BOS is Bronchiolitis obliterans syndrome (BOS) after allogeneic stem cell transplantation
Hospital Foch · 36 participants
📍 France
2024-516796-33-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/05/2026
A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC
Extensive stage small cell lung cancer
Novartis Pharma AG · 25 participants
📍 Spain · France
2025-523276-23-00 on CTIS ↗
Phase II Immune System Diseases Authorised 27/05/2026
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
moderate to severe rheumatoid arthritis (RA)
F. Hoffmann-La Roche AG · 46 participants
📍 Italy · Spain · Germany · France · Denmark · Poland · Belgium
2025-523579-47-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/05/2026
Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas
Sarcoma
Glaxosmithkline Research & Development Limited · 14 participants
📍 France
2025-523997-18-00 on CTIS ↗
Phase III Immune System Diseases Authorised 27/05/2026
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
Moderately to Severely Active Crohn’s Disease
Janssen Cilag International · 302 participants
📍 Slovakia · Germany · Denmark · France · Spain · Italy · Netherlands · Belgium · Poland · Sweden · Austria · Czechia · Hungary
2025-521590-13-00 on CTIS ↗
Phase II Mental Disorders Authorised 27/05/2026
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Maplight Therapeutics Inc. · 85 participants
📍 Italy · Poland · Czechia · Portugal · Bulgaria · France · Slovakia · Romania · Hungary
2025-521757-16-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 26/05/2026
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
Duchenne muscular dystrophy
Solid Biosciences Inc. · 62 participants
📍 Spain · Netherlands · France · Italy · Belgium · Germany
2025-522949-22-00 on CTIS ↗
Phase I/II Neoplasms Authorised 26/05/2026
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Neoplasm malignant
Merck Sharp & Dohme LLC · 21 participants
📍 France · Spain · Sweden · Germany · Italy · Belgium · Denmark
2025-522339-32-00 on CTIS ↗
Phase II Musculoskeletal Diseases Authorised 26/05/2026
POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug
Chronic recurrent multifocal osteomyelitis (CRMO)
Assistance Publique Hopitaux De Paris · 30 participants
📍 France
2023-506420-93-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 26/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
Severe uncontrolled asthma
Generate Biomedicines Inc. · 73 participants
📍 Italy · Slovakia · Spain · Ireland · Belgium · France
2025-524040-35-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 25/05/2026
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
relapsed/refractory multiple myeloma
C4 Therapeutics Inc. · 43 participants
📍 Italy · France · Spain · Poland
2025-524181-26-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/05/2026
Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices (OPIAC)
Intracranial aneurysms
Les Hopitaux Universitaires De Strasbourg · 244 participants
📍 France
2025-524884-18-01 on CTIS ↗
Phase II Neoplasms Authorised 22/05/2026
UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis
Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting
Unicancer · 51 participants
📍 France
2025-521982-29-00 on CTIS ↗
Phase III Neoplasms Authorised 22/05/2026
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy
Unresectable Stage III non-small cell lung cancer without progression
Bristol-Myers Squibb Services Unlimited Company · 279 participants
📍 France · Ireland · Germany · Greece · Bulgaria · Spain · Netherlands · Italy · Sweden · Romania · Hungary · Belgium · Austria · Poland
2025-523576-23-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/05/2026
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
Neoplasms benign malignant and unspecified (incl. cysts and polyps)
Orion Corporation · 85 participants
📍 Finland · Denmark · Spain · France
2025-524620-22-00 on CTIS ↗
Phase II Metabolism Authorised 21/05/2026
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
Adult patients with primary mitochondrial disease
Pharming Technologies B.V. · 117 participants
📍 Belgium · Germany · Czechia · Spain · Denmark · Italy · France
2025-524367-20-00 on CTIS ↗
Phase I Neoplasms Authorised 21/05/2026
First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors
Neoplasms
Glaxosmithkline Research & Development Limited · 52 participants
📍 Spain · Denmark · Finland · France
2025-524165-25-00 on CTIS ↗
Phase III Skin and Connective Tissue Diseases Authorised 20/05/2026
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib
Chronic Spontaneous Urticaria
Novartis Pharma AG · 154 participants
📍 Germany · Spain · France · Poland · Bulgaria · Czechia
2025-524078-40-00 on CTIS ↗
Phase III Immune System Diseases Authorised 20/05/2026
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
Hidradenitis Suppurativa (HS)
Novartis Pharma AG · 307 participants
📍 Portugal · Greece · Germany · Hungary · France · Spain · Bulgaria · Slovakia · Poland · Czechia · Belgium · Italy
2025-523259-72-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 20/05/2026
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Duchenne muscular dystrophy
Avidity Biosciences Inc. · 42 participants
📍 Italy · Germany · France · Spain · Belgium · Poland · Netherlands
2025-523087-20-00 on CTIS ↗
Phase III Neoplasms Authorised 19/05/2026
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
Metastatic hormone-sensitive prostate cancer
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard · 292 participants
📍 Spain · Germany · France · Portugal · Italy
2025-524408-30-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 19/05/2026
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding
VarmX B.V. · 443 participants
📍 Belgium · Germany · Italy · France · Czechia · Bulgaria · Hungary · Spain · Netherlands · Poland · Austria · Estonia · Romania · Portugal · Lithuania
2025-521632-12-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 19/05/2026
PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases
Proteinuric kidney diseases
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 66 participants
📍 Portugal · Greece · Italy · Poland · Estonia · Slovakia · Sweden · Denmark · Belgium · Norway · Romania · France · Spain · Germany · Netherlands · Croatia
2025-523425-17-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations
locally advanced or metastatic NSCLC
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 19 participants
📍 Germany · France · Spain
2025-523567-38-00 on CTIS ↗
Phase II Neoplasms Authorised 19/05/2026
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Patients With Muscle-Invasive Bladder Cancer
AstraZeneca AB · 60 participants
📍 Italy · Spain · France · Netherlands
2024-519246-75-01 on CTIS ↗
Phase III Neoplasms Authorised 19/05/2026
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corp. · 292 participants
📍 Poland · France · Denmark · Norway · Spain · Germany · Belgium · Netherlands · Austria · Italy
2025-523735-19-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 18/05/2026
Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).
Neisseria gonorrhoeae Infections
Assistance Publique Hopitaux De Paris · 360 participants
📍 France
2025-524475-23-00 on CTIS ↗
Phase I Nervous System Diseases Authorised 18/05/2026
A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease
Parkinson's Disease
Mission Therapeutics Limited · 18 participants
📍 Germany · Netherlands · France
2024-517310-15-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 18/05/2026
EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections
Pleural infections
Centre Hospitalier Universitaire Amiens Picardie · 244 participants
📍 France
2025-524697-42-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 18/05/2026
INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an “add-on” Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial
Incremental Haemodialysis
Centre Hospitalier Le Mans · 70 participants
📍 France
2025-524093-41-00 on CTIS ↗
Phase II Bacterial Infections and Mycoses Authorised 18/05/2026
Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV
Asymptomatic anal LGV infection
Centre Hospitalier Universitaire De Bordeaux · 120 participants
📍 France
2025-524978-42-00 on CTIS ↗
Phase I/II Hemic and Lymphatic Diseases Authorised 18/05/2026
mRNA Therapy to restore lymphatic flow in secondary lymphedema
Lymphedema
Centre Hospitalier Universitaire De Toulouse · 9 participants
📍 France
2024-520149-22-00 on CTIS ↗
Phase IV Neoplasms Authorised 18/05/2026
Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”
Gastroenteropancreatic neuroendocrine tumors
Centre De Lutte Contre Le Cancer Eugene Marquis · 40 participants
📍 France
2025-524942-87-00 on CTIS ↗
Phase II Neoplasms Authorised 18/05/2026
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification
Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene
AbbVie Deutschland GmbH & Co. KG · 29 participants
📍 Spain · France · Denmark
2024-518871-74-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 18/05/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC · 398 participants
📍 Italy · Finland · Bulgaria · Greece · Belgium · Estonia · Portugal · Spain · Germany · France · Czechia · Slovakia · Romania · Croatia · Poland · Austria · Netherlands · Denmark · Sweden · Hungary
2025-524316-11-00 on CTIS ↗
Phase II Neoplasms Authorised 18/05/2026
A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation
Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation
Novartis Pharma AG · 14 participants
📍 Spain · France · Germany · Poland · Italy · Netherlands
2025-522138-29-00 on CTIS ↗
Phase IV Respiratory Tract Diseases Authorised 18/05/2026
A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.
Asthma
Chiesi Farmaceutici S.p.A. · 606 participants
📍 Germany · Romania · Italy · Bulgaria · Poland · Slovakia · Spain · France
2025-524289-56-00 on CTIS ↗
Phase III Neoplasms Authorised 18/05/2026
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Relapsed or Refractory Multiple Myeloma
Janssen Cilag International · 157 participants
📍 Spain · Norway · Germany · Greece · France · Italy · Netherlands
2025-522007-18-00 on CTIS ↗
Phase III Neoplasms Authorised 15/05/2026
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 265 participants
📍 Portugal · Norway · Sweden · Bulgaria · France · Belgium · Austria · Germany · Finland · Poland · Romania · Netherlands · Spain · Italy · Hungary · Czechia
2025-523586-18-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/05/2026
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Advanced Solid Tumors
Eikon Therapeutics Inc. · 49 participants
📍 France · Spain · Norway · Italy · Germany · Austria · Poland · Finland
2026-525248-13-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 14/05/2026
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/refractory primary central nervous system lymphoma
Deciphera Pharmaceuticals Inc. · 74 participants
📍 Czechia · Germany · Italy · Belgium · Spain · Poland · Austria · France
2025-523389-26-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
Quetzal Therapeutics LLC · 89 participants
📍 Germany · Poland · Spain · Romania · Italy · France
2025-524810-28-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 13/05/2026
Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy
Multiple System Atrophy
Alterity Therapeutics Limited · 7 participants
📍 France
2025-524317-88-00 on CTIS ↗
Phase I/II Neoplasms Authorised 13/05/2026
Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN
FLT3-mutated Acute Myeloid Leukemia
Centre Hospitalier Universitaire De Bordeaux · 41 participants
📍 France
2024-517130-17-00 on CTIS ↗
Phase III Neoplasms Authorised 13/05/2026
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
advanced or metastatic extrapulmonary neuroendocrine carcinoma
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 144 participants
📍 Portugal · Spain · Poland · Sweden · Italy · Czechia · France · Netherlands · Finland · Denmark · Austria · Germany · Belgium · Norway
2025-523869-22-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 13/05/2026
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis
Prurigo Nodularis
Innocare Pharma Inc. · 56 participants
📍 Belgium · Poland · Germany · France · Austria
2025-523404-74-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 13/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or Overweight and Type 2 Diabetes
F. Hoffmann-La Roche AG · 551 participants
📍 Germany · Romania · Czechia · Poland · Hungary · France · Spain · Italy
2025-523106-32-00 on CTIS ↗
Phase III Neoplasms Authorised 12/05/2026
IMMUNOTIME « EVALUATION OF THE EFFECT OF TIME OF ADMINISTRATION ON THE ACTIVITY ON FIRST LINE OF PEMBROLIZUMAB IN ASSOCIATION WITH CARBOPLATIN PEMETREXED IN METASTATIC NON-SQUAMOUS LUNG CANCER. A RANDOMISED MULTICENTER PHASE III TRIAL»
Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)
Assistance Publique Hopitaux De Paris · 254 participants
📍 France
2025-521891-78-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 12/05/2026
Effect of vasopressin versus norepinephrine on post-operative mean pulmonary arterial pressure following pulmonary endarterectomy surgery, a randomized open label trial
Chronic thromboembolic pulmonary hypertension
Fondation Hopital Saint Joseph · 90 participants
📍 France
2025-525153-39-00 on CTIS ↗
Phase II Neoplasms Authorised 12/05/2026
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
Esophageal squamous cell carcinoma
Merck Sharp & Dohme LLC · 12 participants
📍 Czechia · Germany · France · Norway
2026-525213-31-00 on CTIS ↗
Phase III Neoplasms Authorised 12/05/2026
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 295 participants
📍 Czechia · Sweden · Poland · Netherlands · Greece · Latvia · Finland · Norway · Belgium · Austria · Portugal · Romania · Italy · Estonia · France · Ireland · Germany · Spain · Bulgaria · Hungary
2025-520565-51-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 12/05/2026
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
Psoriatic Arthritis
Takeda Development Center Americas Inc. · 638 participants
📍 Germany · Belgium · Spain · Czechia · Croatia · Portugal · Poland · Latvia · Bulgaria · France · Estonia · Hungary · Italy
2025-522586-30-00 on CTIS ↗
Phase II Neoplasms Authorised 12/05/2026
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Non-small cell lung cancer (NSCLC), Cervical cancer (CC), Melanoma, Hepatocellular carcinoma (HCC), Ovarian cancer (OC), Squamous cell carcinoma of head and neck
Dualitybio Inc. · 102 participants
📍 Italy · Poland · France · Spain · Germany
2025-523895-22-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 11/05/2026
MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
Assistance Publique Hopitaux De Paris · 120 participants
📍 France
2025-521331-36-00 on CTIS ↗
Phase III Neoplasms Authorised 11/05/2026
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms
Eli Lilly & Co. · 486 participants
📍 Netherlands · Hungary · France · Austria · Poland · Italy · Denmark · Romania · Greece · Norway · Czechia · Belgium · Spain · Ireland · Germany
2025-522255-25-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 11/05/2026
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
Chronic rhinosinusitis with nasal polyps
Sanofi-Aventis Recherche & Developpement · 146 participants
📍 Germany · Netherlands · Portugal · Denmark · Sweden · Finland · France · Spain · Austria · Italy · Hungary · Romania · Belgium · Czechia · Poland
2025-522983-33-00 on CTIS ↗
Phase I Neoplasms Authorised 08/05/2026
First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors
Advanced Solid Tumors
Daiichi Sankyo Inc. · 24 participants
📍 France · Spain
2025-521173-13-00 on CTIS ↗
Phase I/II Neoplasms Authorised 08/05/2026
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies
Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals Inc. · 99 participants
📍 Italy · Spain · Germany · France
2025-523399-22-00 on CTIS ↗
Phase III Physical Phenomena Authorised 07/05/2026
A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.
Treatment of moderate to severe glabellar lines
Ipsen Innovation · 230 participants
📍 France · Germany
2025-522618-22-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 07/05/2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight Without Type 2 Diabetes
F. Hoffmann-La Roche AG · 754 participants
📍 Poland · Hungary · France · Belgium · Italy · Netherlands · Czechia · Germany · Spain
2025-523104-71-00 on CTIS ↗
Phase II Neoplasms Authorised 06/05/2026
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
Non-Small Cell Lung Cancer
AstraZeneca AB · 70 participants
📍 France · Italy · Spain
2025-524843-11-00 on CTIS ↗
Phase I Neoplasms Authorised 05/05/2026
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
Small Cell Lung Cancer
Amgen Inc. · 53 participants
📍 Spain · Germany · Poland · Belgium · France
2025-522888-15-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/05/2026
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
Persistent Corneal Epithelial Defect (PCED)
Dompe' Farmaceutici S.p.A. · 91 participants
📍 Czechia · Italy · Netherlands · Poland · Germany · Spain · Hungary · France
2025-523443-35-00 on CTIS ↗
Phase III Immune System Diseases Authorised 05/05/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Janssen Cilag International · 271 participants
📍 Denmark · Hungary · Portugal · Italy · Norway · Greece · Slovakia · Czechia · France · Poland · Bulgaria · Germany · Spain · Romania · Finland
2025-523552-31-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 04/05/2026
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)
Obesity
Novo Nordisk A/S · 270 participants
📍 Denmark · France · Germany · Belgium
2024-520440-42-00 on CTIS ↗
Phase II Eye Diseases Authorised 04/05/2026
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
Geographic atrophy secondary to age-related macular degeneration
Novartis Pharma AG · 142 participants
📍 Bulgaria · Romania · Germany · Czechia · Spain · Poland · Italy · Hungary · France
2025-523704-77-00 on CTIS ↗
Phase III Immune System Diseases Authorised 04/05/2026
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy
IgA nephropathy
Novartis Pharma AG · 69 participants
📍 Belgium · France · Czechia · Croatia · Greece · Germany · Italy · Spain
2024-519638-22-00 on CTIS ↗
Phase III Neoplasms Authorised 04/05/2026
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC · 311 participants
📍 Denmark · Spain · Netherlands · Germany · France · Czechia · Poland · Italy · Greece
2024-516993-31-00 on CTIS ↗
Phase II Neoplasms Authorised 30/04/2026
"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"
gastric cancer
Centre Hospitalier Universitaire De Bordeaux · 40 participants
📍 France
2025-524434-25-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 30/04/2026
Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE
Neurology
Hospices Civils De Lyon · 50 participants
📍 France
2025-524511-36-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 30/04/2026
A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors
refractory hypotension in distributive shock
Paion Pharma GmbH · 143 participants
📍 Italy · Germany · France · Spain
2025-523750-14-00 on CTIS ↗
Phase III Neoplasms Authorised 30/04/2026
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed or Refractory Multiple Myeloma
AstraZeneca AB · 153 participants
📍 Norway · Poland · Spain · Germany · France · Italy
2025-523285-25-00 on CTIS ↗
Phase III Mental Disorders Authorised 28/04/2026
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
Xenon Pharmaceuticals Inc. · 70 participants
📍 Bulgaria · Germany · France · Spain
2025-522872-10-00 on CTIS ↗
Phase I Neoplasms Authorised 28/04/2026
​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors
Amgen Inc. · 77 participants
📍 Spain · France · Belgium
2025-524056-63-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 28/04/2026
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc. · 94 participants
📍 Spain · Poland · Italy · Belgium · Latvia · Denmark · Czechia · Germany · France · Netherlands · Portugal · Ireland · Greece
2024-520218-23-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
CIRCULATE III - Tailoring the decision for adjuvant chemotherapy using circulating tumour DNA, in patients with stage III colorectal cancer
Stage III colorectal cancer
Unicancer · 300 participants
📍 France · Sweden
2025-521045-24-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations
Merck Sharp & Dohme LLC · 37 participants
📍 Czechia · Spain · Poland · Belgium · Finland · Germany · France · Netherlands · Hungary · Denmark
2025-524160-38-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 28/04/2026
ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial
Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation
Assistance Publique Hopitaux De Paris · 1008 participants
📍 France
2025-520842-31-00 on CTIS ↗
Phase II Hemic and Lymphatic Diseases Authorised 28/04/2026
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
Sickle Cell Disease
CSL Behring LLC · 12 participants
📍 Belgium · Netherlands · France · Italy
2025-521154-42-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases
F. Hoffmann-La Roche AG · 237 participants
📍 Belgium · France · Italy · Austria · Romania · Poland · Portugal · Czechia · Germany · Spain · Hungary
2025-524498-17-00 on CTIS ↗
Phase II Mental Disorders Authorised 28/04/2026
Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)
The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.
Assistance Publique Hopitaux De Paris · 24 participants
📍 France
2025-521967-11-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 28/04/2026
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1
Dyne Therapeutics Inc. · 72 participants
📍 Netherlands · Spain · Italy · Denmark · Germany · Belgium · France
2025-522957-20-00 on CTIS ↗
Phase III Neoplasms Authorised 28/04/2026
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
Ovarian cancer
Merck Sharp & Dohme LLC · 349 participants
📍 Norway · Ireland · Spain · Greece · France · Poland · Denmark · Austria · Hungary · Belgium · Czechia · Finland · Germany · Italy · Sweden
2023-508047-40-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/04/2026
A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)
Classical Homocystinuria
Travere Therapeutics Inc. · 22 participants
📍 Belgium · Ireland · Spain · Italy · Germany · France · Portugal · Poland
2023-504135-40-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/04/2026
Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
Obesity
Novo Nordisk A/S · 325 participants
📍 Belgium · Germany · Bulgaria · France · Spain · Denmark · Italy · Netherlands
2025-523804-62-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 27/04/2026
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines Inc. · 98 participants
📍 France · Spain · Italy · Germany
2025-523495-23-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 27/04/2026
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)
Cancer-Associated Thrombosis (CAT).
Regeneron Pharmaceuticals Inc. · 324 participants
📍 Belgium · Czechia · France · Romania · Germany · Poland · Bulgaria · Spain
2024-519298-21-00 on CTIS ↗
Phase II Respiratory Tract Diseases Authorised 27/04/2026
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A. · 103 participants
📍 Belgium · Germany · Italy · Czechia · Bulgaria · Netherlands · France · Portugal · Poland · Spain · Romania
2024-514246-37-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 27/04/2026
SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years
Craniopharyngioma
Centre Hospitalier Universitaire D'Angers · 50 participants
📍 France
2024-511114-20-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 27/04/2026
Methylphenidate for Early Awakening in Coma (MEAWAKE)
Coma due to acute brain injury
Rigshospitalet · 324 participants
📍 Austria · Denmark · Germany · France
2025-524937-19-00 on CTIS ↗
Phase I/II Neoplasms Authorised 27/04/2026
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
Novartis Pharma AG · 21 participants
📍 Italy · Spain · Germany · Netherlands · France · Denmark · Czechia
2025-522019-40-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 24/04/2026
Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM
Neurology
Hospices Civils De Lyon · 165 participants
📍 France
2025-524602-15-00 on CTIS ↗
Phase III Not possible to specify Authorised 24/04/2026
ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial
Septic shock
Hospices Civils De Lyon · 360 participants
📍 France
2025-524122-18-00 on CTIS ↗
Phase II Immune System Diseases Authorised 23/04/2026
A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease
Kidney disease
Medizinische Universitaet Innsbruck · 48 participants
📍 Germany · Austria · France
2025-520641-69-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/04/2026
COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients
Vulvar Squamous Cell Carcinoma (VSCC) patients
Centre Leon Berard · 50 participants
📍 France
2025-524759-29-00 on CTIS ↗
Phase I/II Neoplasms Authorised 22/04/2026
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Advanced or unresectable Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb Services Unlimited Company · 47 participants
📍 Poland · Spain · Germany · France · Italy
2025-523602-33-00 on CTIS ↗
Phase I Immune System Diseases Authorised 22/04/2026
Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis
Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)
Genentech Inc. · 17 participants
📍 Italy · Spain · France · Germany
2025-522904-26-00 on CTIS ↗
Phase III Musculoskeletal Diseases Authorised 21/04/2026
Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)
Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.
Assistance Publique Hopitaux De Paris · 187 participants
📍 France
2025-520678-20-00 on CTIS ↗
Phase II Neoplasms Authorised 21/04/2026
NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial
Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.
Unicancer · 630 participants
📍 France
2025-523683-20-00 on CTIS ↗
Phase III Not possible to specify Authorised 21/04/2026
A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia
Chemotherapy induced thrombocytopenia
Jiangsu Hengrui Pharmaceuticals Co. Ltd. · 58 participants
📍 France · Romania · Poland · Spain · Bulgaria
2025-524209-34-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 21/04/2026
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension
Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharma AG · 138 participants
📍 Netherlands · Germany · Spain · Italy · France · Belgium
2025-523481-24-00 on CTIS ↗
Phase I/II Neoplasms Authorised 21/04/2026
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
Institut De Recherches Internationales Servier IRIS · 105 participants
📍 France · Spain · Denmark · Italy
2025-523474-16-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 20/04/2026
KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial
Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation
Assistance Publique Hopitaux De Paris · 640 participants
📍 France
2025-523149-80-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
treatment-naive Chronic Lymphocytic Leukemia
BeOne Medicines I GmbH · 186 participants
📍 Netherlands · Poland · Italy · Germany · Spain · Romania · Czechia · France · Sweden
2025-524366-21-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 20/04/2026
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Homeostatic iron regulator gene-related hereditary hemochromatosis
CSL Behring LLC · 50 participants
📍 Austria · Poland · Spain · Germany · France · Ireland · Romania · Belgium · Italy · Czechia · Netherlands
2025-523793-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 20/04/2026
Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases
colon carcinoma metastases
HepaRegeniX GmbH · 40 participants
📍 France · Spain · Germany
2025-523630-59-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 102 participants
📍 Spain · France · Belgium · Germany
2025-522913-45-00 on CTIS ↗
Phase I Neoplasms Authorised 20/04/2026
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
AbbVie Deutschland GmbH & Co. KG · 18 participants
📍 Spain · Hungary · Czechia · France · Italy · Belgium
2024-520125-36-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
Locally advanced/metastatic urothelial carcinoma
Merck Sharp & Dohme LLC · 265 participants
📍 Netherlands · Greece · Italy · Germany · Spain · Belgium · Sweden · France
2024-520014-22-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 20/04/2026
C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY
hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)
Pfizer Inc. · 31 participants
📍 Italy · Germany · France · Spain · Sweden · Greece
2025-523660-21-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/04/2026
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A., Prilenia Therapeutics B.V. · 420 participants
📍 Belgium · Netherlands · Poland · France · Germany · Ireland · Italy · Sweden · Spain
2025-524002-16-00 on CTIS ↗
Phase III Neoplasms Authorised 20/04/2026
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
Eli Lilly & Co. · 197 participants
📍 Italy · Poland · Denmark · Czechia · France · Hungary · Germany · Netherlands · Spain
2025-522855-25-00 on CTIS ↗
Phase II Neoplasms Authorised 17/04/2026
IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease
Non Small Cell Lung Cancer, Interstitial Lung Disease
Intergroupe Francophone De Cancerologie Thoracique · 108 participants
📍 France
2025-522790-10-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 17/04/2026
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
MaaT PHARMA · 18 participants
📍 Netherlands · Italy · France · Spain
2025-524302-15-00 on CTIS ↗
Phase III Neoplasms Authorised 17/04/2026
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
Ovarian cancer
Incyte Corp. · 308 participants
📍 Ireland · Poland · France · Netherlands · Spain · Italy · Germany · Belgium
2025-522748-42-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 17/04/2026
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
HFpEF or HFmrEF and obesity
Novo Nordisk A/S · 1992 participants
📍 Denmark · Greece · Bulgaria · Italy · Netherlands · Spain · Poland · Czechia · Germany · France
2025-523717-29-00 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 17/04/2026
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Myelodysplastic neoplasms/syndromes (MDS)
Takeda Development Center Americas Inc. · 114 participants
📍 France · Belgium · Germany · Italy · Bulgaria · Ireland · Lithuania · Norway · Romania · Hungary · Spain · Greece · Poland · Netherlands
2025-523544-12-00 on CTIS ↗
Phase II Neoplasms Authorised 16/04/2026
METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0
METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)
Unicancer · 55 participants
📍 France
2025-522655-26-00 on CTIS ↗
Phase IV Digestive System Diseases Authorised 16/04/2026
OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE
Crohn's disease
i-GETAID · 210 participants
📍 France
2025-524573-16-00 on CTIS ↗
Phase I/II Neoplasms Authorised 16/04/2026
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
Advanced HR+/HER- breast cancer
Novartis Pharma AG · 55 participants
📍 Italy · Germany · France · Czechia · Denmark · Spain
2025-521911-38-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 16/04/2026
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia
Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
Larimar Therapeutics Inc. · 18 participants
📍 France
2025-521628-31-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/france (Accessed: 6 July 2026).

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker.